


A theoretical paper has been released suggesting that as companies replace labor with artificial intelligence (AI), costs decrease, but the reduction in consumption by laid-off workers could spread throughout the market.
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.
💳 Cryptocurrencies and traditional payment systems are merging on the same infrastructure. 💵 Stablecoins are increasingly used in cross-border payments. 🏦 Banks are testing tokenized deposit solutions. 🔐 Compliance and regulatory requirements are now a core part of the systems.